Jennifer A. Schoborg

Jennifer A. Schoborg

Auto-generated profile, based on publicly available information

Jennifer A. Schoborg

Department of Chemical and Biological Engineering, Northwestern University, Evanston, Illinois

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2017 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
JSJennifer A. Schoborg
Jennifer A. Schoborg
JHJasmine M. Hershewe
Jasmine M. Hershewe
JSJessica C. Stark
Jessica C. Stark
WKWeston Kightlinger
Weston Kightlinger
JKJames E. Kath
James E. Kath
MJMichael C. Jewett
Michael C. Jewett

2 October 2015 in Biotechnology Journal
Verified
Journal Article
Closed access
PDF file
CSChallise J. Sullivan
Challise J. Sullivan
EPErik D. Pendleton
Erik D. Pendleton
HSHenri H. Sasmor
Henri H. Sasmor
WHWilliam L. Hicks
William L. Hicks
JFJohn B. Farnum
John B. Farnum
JDJohn Dresios
John Dresios

10 December 2013 in Biotechnology Journal
Verified
Journal Article
Closed access
PDF file
JSJennifer A. Schoborg
Jennifer A. Schoborg
CHC. Eric Hodgman
C. Eric Hodgman
MAMark J. Anderson
Mark J. Anderson
MJMichael C. Jewett
Michael C. Jewett

1 March 2016 in Synthetic and Systems Biotechnology
Verified
Journal Article
Open access
JSJennifer A. Schoborg
Jennifer A. Schoborg
LCLauren G. Clark
Lauren G. Clark
ACAlaksh Choudhury
Alaksh Choudhury
CHC. Eric Hodgman
C. Eric Hodgman
MJMichael C. Jewett
Michael C. Jewett
Cell-free protein synthesis (CFPS) systems from crude lysates have benefitted from modifications to their enzyme composition. For example, functionally deleting enzymes in the source strain that are deleterious to CFPS can improve protein synthesis yields. However, making such modifications can take substantial time. As a proof-of-concept to accelerate prototyping capabilities, we assessed the feasibility of using the yeast knockout collection to identify negative effectors in a Saccharomyces cerevisiae CFPS platform. We analyzed extracts made from six deletion strains that targeted the single deletion of potentially negative effectors (e.g., nucleases). We found a statistically significant increase in luciferase yields upon loss of function of GCN3, PEP4, PPT1, NGL3, and XRN1 with a maximum increase of over 6-fold as compared to the wild type. Our work has implications for yeast CFPS and for rapidly prototyping strains to enable cell-free synthetic biology applications.

15 April 2015 in Protein Engineering, Design and Selection
Verified
Journal Article
Open access
PHPete Heinzelman
Pete Heinzelman
JSJennifer A. Schoborg
Jennifer A. Schoborg
MJMichael C. Jewett
Michael C. Jewett
Systemic injection of granulocyte colony-stimulating factor (G-CSF) has yielded encouraging results in treating Alzheimer's Disease (AD) and other central nervous system (CNS) disorders. Making G-CSF a viable AD therapeutic will, however, require increasing G-CSF's ability to stimulate neurons within the brain. This objective could be realized by increasing transcytosis of G-CSF across the blood brain barrier (BBB). An established correlation between G-CSF receptor (G-CSFR) binding pH responsiveness and increased recycling of G-CSF to the cell exterior after endocytosis motivated development of G-CSF variants with highly pH responsive G-CSFR binding affinities. These variants will be used in future validation of our hypothesis that increased BBB transcytosis can enhance G-CSF therapeutic efficacy. Flow cytometric screening of a yeast-displayed library in which G-CSF/G-CSFR interface residues were mutated to histidine yielded a G-CSF triple His mutant (L109H/D110H/Q120H) with highly pH responsive binding affinity. This variant's KD, measured by surface plasmon resonance (SPR), increases ∼20-fold as pH decreases from 7.4 to below histidine's pKa of ∼6.0; an increase 2-fold greater than for previously reported G-CSF His mutants. Cell-free protein synthesis (CFPS) enabled expression and purification of soluble, bioactive G-CSF triple His variant protein, an outcome inaccessible via Escherichia coli inclusion body refolding. This purification and bioactivity validation will enable future identification of correlations between pH responsiveness and transcytosis in BBB cell culture model and animal experiments. Furthermore, the library screening and CFPS methods employed here could be applied to developing other pH responsive hematopoietic or neurotrophic factors for treating CNS disorders.

5 June 2017 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJennifer A. Schoborg
Jennifer A. Schoborg
JHJasmine Hershewe
Jasmine Hershewe
JSJessica C. Stark
Jessica C. Stark
WKWeston Kightlinger
Weston Kightlinger
JKJames E. Kath
James E. Kath
MJMichael C. Jewett
Michael C. Jewett
Protein glycosylation, or the attachment of sugar moieties (glycans) to proteins, is important for protein stability, activity, and immunogenicity. However, understanding the roles and regulations of site-specific glycosylation events remains a significant challenge due to several technological limitations. These limitations include a lack of available tools for biochemical characterization of enzymes involved in glycosylation. A particular challenge is the synthesis of oligosaccharyltransferases (OSTs), which catalyze the attachment of glycans to specific amino acid residues in target proteins. The difficulty arises from the fact that canonical OSTs are large (>70 kDa) and possess multiple transmembrane helices, making them difficult to overexpress in living cells. Here, we address this challenge by establishing a bacterial cell-free protein synthesis platform that enables rapid production of a variety of OSTs in their active conformations. Specifically, by using lipid nanodiscs as cellular membrane mimics, we obtained yields of up to 440 µg/mL for the single-subunit OST enzyme, ‘Protein glycosylation B’ (PglB) from Campylobacter jejuni , as well as for three additional PglB homologs from Campylobacter coli, Campylobacter lari , and Desulfovibrio gigas . Importantly, all of these enzymes catalyzed N -glycosylation reactions in vitro with no purification or processing needed. Furthermore, we demonstrate the ability of cell-free synthesized OSTs to glycosylate multiple target proteins with varying N -glycosylation acceptor sequons. We anticipate that this broadly applicable production method will advance glycoengineering efforts by enabling preparative expression of membrane-embedded OSTs from all kingdoms of life.